Aurobindo Pharma has made voluntary recall of multiple injectables manufactured for its US subsidiary.
The company said reason for the recall is lack of assurance of sterility as well as leaking bags.
Unit 4 is the most important injectable unit of the company and has received nine observations from US Food and Drug Administration (US FDA).
US FDA publishes weekly report of all the recalls which are being undertaken in the US market for voluntary reasons or initiated by the US FDA.
These Aurobindo recalls are a class-II recalls, which are voluntary in nature.